Ashley Chan

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.

High-grade immune-related adverse effects occurred in 18.9% of older patients with early-stage breast cancer treated with immune checkpoint inhibitors, according to a multi-institutional study.

Second-generation BTK inhibitors exhibited a significantly lower incidence of cardiac adverse effects in B-cell malignancies, according to a meta analysis.

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

Lenvatinib, pembrolizumab, and TACE outperformed placebo plus TACE in progression-free survival for intermediate-stage hepatocellular carcinoma.

Oral azacitidine had a similar safety profile across the 200-mg and 300-mg groups in lower- to intermediate-risk MDS.

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

After radical prostatectomy, patients with prostate cancer treated with abiraterone acetate plus prednisone and apalutamide had improved outcomes without a significant impact on their health-related quality of life.

The major molecular response rate for asciminib at week 156 continued to be higher than with bosutinib.